Fulcrum Therapeutics, Inc

(NASDAQ:FULC)

Latest On Fulcrum Therapeutics, Inc (FULC):

Date/Time Type Description Signal Details
2023-05-24 17:06 ESTNewsFulcrum Therapeutics: FSHD Steadily Advancing In Phase 3, Optionality With SCDN/A
2023-05-16 00:01 ESTNewsFulcrum Therapeutics, Inc. (FULC) Q1 2023 Earnings Call TranscriptN/A
2023-05-15 10:14 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.41 beats by $0.05, revenue of $0.3M misses by $0.68MN/A
2023-05-15 10:14 ESTNewsFulcrum Therapeutics appoints new executive chiefN/A
2023-05-05 01:13 ESTNewsFulcrum slips as Goldman Sachs downgrades on limited catalyst pathN/A
2023-04-25 17:38 ESTNewsFulcrum Therapeutics: Barrage Of Bad News In 2023 But Key Catalysts RemainN/A
2023-04-05 22:41 ESTNewsFulcrum Therapeutics CFO resignsN/A
2023-03-10 23:32 ESTNewsFulcrum Therapeutics downgraded to neutral at Credit Suisse on sickle cell candidateN/A
2023-03-10 23:31 ESTNewsFulcrum Therapeutics, Inc. (FULC) Q4 2022 Earnings Call TranscriptN/A
2023-03-09 16:52 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.50 misses by $0.01, revenue of $0.7M misses by $1.19MN/A
2023-03-09 16:52 ESTNewsFulcrum plunges 23% after Q4 update as medical chief departsN/A
2023-02-24 17:52 ESTNewsFulcrum Therapeutics plunges 55% on clinical hold for sickle cell treatmentsN/A
2023-02-13 20:23 ESTNewsFulcrum's Losmapimod: A Potential Aid, But Its Ability To Modify The Disease Remains UncertainN/A
2023-01-18 07:27 ESTNewsFulcrum Therapeutics shares slide after pricing $125M upsized stock offeringN/A
2023-01-17 20:15 ESTNewsFulcrum Therapeutics commences $100M underwritten public offering of sharesN/A
2023-01-04 19:34 ESTNewsFulcrum Therapeutics names new CEO and provides business outlookN/A
2022-11-12 22:51 ESTNewsFulcrum Therapeutics, Inc. (FULC) Q3 2022 Earnings Call TranscriptN/A
2022-11-08 12:30 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.51 beats by $0.11, revenue of $1.18M misses by $1.36MN/A
2022-11-07 19:00 ESTNewsFulcrum Therapeutics names new chief medical officer, chief scientific officerN/A
2022-08-16 08:01 ESTNewsFulcrum Therapeutics stock dips on offering of $75M sharesN/A
2022-08-16 08:01 ESTNewsFulcrum prices ~$75M stock offeringN/A
2022-08-12 02:43 ESTNewsFulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-11 09:44 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06MN/A
2022-07-11 19:26 ESTNewsFulcrum Therapeutics says chief medical officer Christopher Morabito to leaveN/A
2022-07-06 05:55 ESTNewsFulcrum begins dosing in late-stage study of losmapimod for rare muscle disorderN/A
2022-06-28 04:00 ESTNewsFulcrum Therapeutics: Value Loss On SCD Data Update Is TellingN/A
2022-06-10 23:46 ESTNewsFulcrum crashes 48% after announcing early-stage data sickle cell disease candidateN/A
2022-06-08 03:53 ESTNewsFulcrum gains as Merck ends deal for lung disease candidatesN/A
2022-05-10 06:03 ESTNewsFulcrum Therapeutics' (FULC) CEO Bryan Stuart on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-09 10:26 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.64 misses by $0.02, revenue of $2.6M misses by $1.34MN/A
2022-03-08 13:53 ESTNewsFulcrum rises as Oppenheimer highlights sickle cell disease candidateN/A
2022-03-03 11:48 ESTNewsFulcrum Therapeutics GAAP EPS of -$0.58 beats by $0.09, revenue of $5.06M beats by $1.54MN/A
2022-03-03 11:48 ESTNewsFulcrum plans phase 3 trial of losmapimod to treat rare muscle disorderN/A
2022-03-03 11:48 ESTNewsFulcrum Therapeutics, Inc.'s (FULC) CEO Bryan Stuart On Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-11 21:58 ESTNewsFulcrum Therapeutics grants inducement options to one new employeeN/A
2022-01-08 15:26 ESTNewsBiogen, Galapagos and Ultragenyx among key biotech calls at Morgan Stanley for 2022N/A
2022-01-04 13:05 ESTNewsFulcrum Therapeutics hires CFON/A
2021-11-06 20:44 ESTNewsFulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q3 2021 results - Earnings Call TranscriptN/A
2021-09-03 15:55 ESTNewsFulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry PointN/A
2021-08-12 17:25 ESTNewsFulcrum Therapeutics raises $125M via equity offeringN/A
2021-08-11 21:00 ESTNewsBluebird bio price target cut; Fulcrum upgraded as Morgan Stanley shakes up SCD coverageN/A
2021-08-11 01:17 ESTNewsFulcrum Therapeutics surges on early-stage results for sickle cell disease therapyN/A
2021-08-11 01:16 ESTNewsFulcrum Therapeutics, Inc. (FULC) CEO Bryan Stuart on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-11 01:15 ESTNewsFulcrum Therapeutics more than doubles as Stifel raises price targetN/A
2021-08-11 01:15 ESTNewsFulcrum Therapeutics shares under pressure after $100M capital raiseN/A
2021-07-21 09:26 ESTNewsFulcrum Therapeutics reports results mid-stage losmapimod study in rare disabling diseaseN/A
2021-07-21 09:26 ESTNewsStifel nearly doubles Fulcrum price target, assumes 354% upsideN/A
2021-07-21 09:24 ESTNewsMRIN, ALT, FLXN and FULC among after-hours moversN/A
2021-05-06 12:07 ESTNewsFulcrum Therapeutics beats on revenueN/A
2021-05-06 12:06 ESTNewsFulcrum Therapeutics has a new medical chiefN/A

About Fulcrum Therapeutics, Inc (FULC):

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

FULC Quotes by TradingView

See Advanced Chart

General

  • Name Fulcrum Therapeutics, Inc
  • Symbol FULC
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 73
  • Fiscal Year EndDecember
  • IPO Date2019-07-18
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Web URLhttp://www.fulcrumtx.com
View More

Valuation

  • Trailing PE 267
  • Price/Sales (Trailing 12 Mt.) 34.37
  • Price/Book (Most Recent Quarter) 4.11
  • Enterprise Value Revenue 31.49
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.87
  • Next Year EPS Estimate -$3.06
  • Next Quarter EPS Estimate -$0.66
  • Operating Margin -812%
  • Return on Assets -37%
  • Return on Equity -78%
  • Revenue 8.82 million
  • Earnings Per Share -$50.40
  • Revenue Per Share $0.35
  • Gross Profit -46839000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 405.79 million
  • EBITDA -67074000
  • PE Ratio -26.37
  • Analyst Target Price $18
  • Book Value Per Share $4.53
View More

Share Statistics

  • Shares Outstanding 32.67 million
  • Shares Float 18.96 million
  • % Held by Insiders 3552%
  • % Held by Institutions 76.11%
  • Shares Short 690946
  • Shares Short Prior Month 724097
  • Short Ratio 4.81
  • Short % of Float 3%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • 52 Week High $22.39
  • 52 Week Low $7.01
  • 50 Day Moving Average 12.75
  • 200 Day Moving Average 11.21
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Fulcrum Therapeutics, Inc (FULC) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Fulcrum Therapeutics, Inc (FULC) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$4.23 million-$0.63-$0.7313.1%
2020-09-302020-11-10$N/A-$0.70-$0.64-9.8%
2020-06-302020-08-11$N/A-$0.66-$0.7511.61%
2020-03-312020-05-13$750000-$0.81-$0.76-6.58%
2019-12-312020-03-05$N/A-$0.71-$0.8819.62%
2019-09-302019-11-14$N/A-$0.97-$0.72-34.72%
2019-06-302019-08-26$N/A-$0.71-$0.755.33%

Fulcrum Therapeutics, Inc (FULC) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Fulcrum Therapeutics, Inc (FULC) Chart:

Fulcrum Therapeutics, Inc (FULC) News:

Below you will find a list of latest news for Fulcrum Therapeutics, Inc (FULC) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Fulcrum Therapeutics, Inc (FULC) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-09-1810CALL0 2260.12TRUE00
2026-09-1820CALL0 0321.03TRUE00
2026-09-1830CALL0 3637.72TRUE00
2026-09-1840CALL0 1381107.73FALSE00
2026-09-1850.1CALL0 222141.81FALSE00
2026-09-1860CALL0 1177.43FALSE00
2026-09-1870CALL0 41204.54FALSE00
2026-09-1880CALL0 61226.44FALSE00
2026-09-1890CALL0 16244.78FALSE00
2026-09-18100CALL0 1260.53FALSE00
2026-09-18110CALL0 7274.32FALSE00
2026-09-18120CALL0 1286.56FALSE00
2026-09-18130CALL0 0297.56FALSE00
2026-09-18140CALL0 0307.53FALSE00
2026-09-18150CALL0 20316.64FALSE00
2026-09-18160CALL0 20325.03FALSE00
2026-09-18170CALL0 1332.79FALSE00
2026-09-18180CALL0 1340.01FALSE00
2026-09-18200CALL0 0353.08FALSE00
2026-09-1810PUT0 0521.4FALSE00
2026-09-1820PUT0 65276.72FALSE00
2026-09-1830.07PUT0 309970.55FALSE00
2026-09-1840PUT0 1685.92TRUE00
2026-09-1850PUT0 083.41TRUE00
2026-09-1860PUT0 084.87TRUE00
2026-09-1870PUT0 9129.9TRUE00
2026-09-1880PUT0 5115.42TRUE00
2026-09-1890PUT0 0130.19TRUE00
2026-09-18100PUT0 2152.41TRUE00
2026-09-18110PUT0 0164.38TRUE00
2026-09-18120PUT0 0175.22TRUE00
2026-09-18130PUT0 0185.13TRUE00
2026-09-18140PUT0 0194.28TRUE00
2026-09-18150PUT0 0300.95TRUE00
2026-09-18160PUT0 0200.29TRUE00
2026-09-18170PUT0 0207.58TRUE00
2026-09-18180PUT0 0214.45TRUE00
2026-09-18200PUT0 0227.14TRUE00
2026-12-1810CALL0 3118.11TRUE00
2026-12-1820CALL0 1121.34TRUE00
2026-12-1830CALL0 3128.5TRUE00
2026-12-1840CALL0 370968.14FALSE00
2026-12-1850CALL0 102104.93FALSE00
2026-12-1860CALL0 0114.87FALSE00
2026-12-1870CALL0 0130.84FALSE00
2026-12-1880CALL0 0143.72FALSE00
2026-12-1890CALL0 0138.89FALSE00
2026-12-18100CALL0 0163.75FALSE00
2026-12-18110CALL0 0171.84FALSE00
2026-12-18120CALL0 0179.02FALSE00
2026-12-18130CALL0 0185.46FALSE00
2026-12-18140CALL0 0174.82FALSE00
2026-12-18150CALL0 1196.63FALSE00
2026-12-18160CALL0 0184.84FALSE00
2026-12-1810PUT0 0299.69FALSE00
2026-12-1820PUT0 1180.52FALSE00
2026-12-1830PUT0 218112.42FALSE00
2026-12-1840PUT0 0149.86TRUE00
2026-12-1850PUT0 0160.46TRUE00
2026-12-1860PUT0 0166.13TRUE00
2026-12-1870PUT0 080.81TRUE00
2026-12-1880PUT0 0102.43TRUE00
2026-12-1890PUT0 0113.19TRUE00
2026-12-18100PUT0 298.33TRUE00
2026-12-18110PUT0 0106.12TRUE00
2026-12-18120PUT0 0113.2TRUE00
2026-12-18130PUT0 0119.68TRUE00
2026-12-18140PUT0 0125.68TRUE00
2026-12-18150PUT0 0146.72TRUE00
2026-12-18160PUT0 0131.68TRUE00
2027-01-1510CALL0 3104.05TRUE00
2027-01-1520CALL0 30178.2TRUE00
2027-01-1530CALL0 30284.53TRUE00
2027-01-1540CALL0 8464.08FALSE00
2027-01-1550CALL0 62369.67FALSE00
2027-01-1560CALL0 1111.97FALSE00
2027-01-1570CALL0 86116.14FALSE00
2027-01-1580CALL0 0127.83FALSE00
2027-01-1590CALL0 2137.61FALSE00
2027-01-15100CALL0 473146FALSE00
2027-01-15110CALL0 0153.34FALSE00
2027-01-15120CALL0 21159.85FALSE00
2027-01-15150CALL0 3933163.65FALSE00
2027-01-15170CALL0 17172.06FALSE00
2027-01-15200CALL0 1198.13FALSE00
2027-01-15220CALL0 0204.29FALSE00
2027-01-15250CALL0 41253.45FALSE00
2027-01-15270CALL0 91258.35FALSE00
2027-01-1510PUT0 0117.07FALSE00
2027-01-1520PUT0 0164.76FALSE00
2027-01-1530PUT0 28105.96FALSE00
2027-01-1540PUT0 282.3TRUE00
2027-01-1550PUT0 123101.75TRUE00
2027-01-1560PUT0 072.59TRUE00
2027-01-1570PUT0 190.34TRUE00
2027-01-1580PUT0 086.36TRUE00
2027-01-1590PUT0 096.05TRUE00
2027-01-15100PUT0 091.88TRUE00
2027-01-15110PUT0 099.15TRUE00
2027-01-15120PUT0 0128.45TRUE00
2027-01-15150PUT0 0136.5TRUE00
2027-01-15170PUT0 0132.34TRUE00
2027-01-15200PUT0 0144.86TRUE00
2027-01-15220PUT0 0152.27TRUE00
2027-01-15250PUT0 0157.06TRUE00
2027-01-15270PUT0 0163.03TRUE00
2027-03-1910CALL0 0104.2TRUE00
2027-03-1920CALL0 040.62TRUE00
2027-03-1931.16CALL40 078.66TRUE1.160
2027-03-1940CALL0 1690.3FALSE00
2027-03-1950CALL0 488.55FALSE00
2027-03-1960CALL0 1128.45FALSE00
2027-03-1970CALL0 1139.07FALSE00
2027-03-1910PUT0 0267.3FALSE00
2027-03-1920PUT0 0157.19FALSE00
2027-03-1930PUT0 0104.57FALSE00
2027-03-1940PUT0 097.51TRUE00
2027-03-1950PUT0 0105.16TRUE00
2027-03-1960PUT0 074.45TRUE00
2027-03-1970PUT0 0130.56TRUE00

Latest FULC Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST48$4.18
Jun 13, 2022 7:59 PM EST10$4.18
Jun 13, 2022 7:59 PM EST100$4.185
Jun 13, 2022 7:59 PM EST100$4.18
Jun 13, 2022 7:59 PM EST112$4.18

Fulcrum Therapeutics, Inc (FULC) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320018278/0000899243-20-018278-index.htm
2019-05-29UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680581/000000000019009042/0000000000-19-009042-index.htm
2019-06-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680581/000000000019009993/0000000000-19-009993-index.htm
2020-06-24UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680581/000000000020005645/0000000000-20-005645-index.htm
2020-08-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1680581/000000000020007385/0000000000-20-007385-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000031506620000982/0000315066-20-000982-index.htm
2020-09-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000089914020000435/0000899140-20-000435-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319019806/0000899243-19-019806-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319019807/0000899243-19-019807-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319019809/0000899243-19-019809-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319020026/0000899243-19-020026-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319020029/0000899243-19-020029-index.htm
2019-07-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924319020073/0000899243-19-020073-index.htm
2020-01-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320000461/0000899243-20-000461-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320000462/0000899243-20-000462-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320002034/0000899243-20-002034-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320002035/0000899243-20-002035-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320002037/0000899243-20-002037-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320002040/0000899243-20-002040-index.htm
2020-01-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320002041/0000899243-20-002041-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320003272/0000899243-20-003272-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320005299/0000899243-20-005299-index.htm
2020-02-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320005300/0000899243-20-005300-index.htm
2020-02-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm
2020-03-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/0000899243-20-006590-index.htm
2020-05-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320012820/0000899243-20-012820-index.htm
2020-05-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/0000899243-20-012822-index.htm
2020-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014415/0000899243-20-014415-index.htm
2020-05-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014416/0000899243-20-014416-index.htm
2020-05-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014552/0000899243-20-014552-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014719/0000899243-20-014719-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014721/0000899243-20-014721-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015063/0000899243-20-015063-index.htm
2020-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm
2020-06-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015437/0000899243-20-015437-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015784/0000899243-20-015784-index.htm
2020-06-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320015959/0000899243-20-015959-index.htm
2020-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/0000899243-20-016382-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016496/0000899243-20-016496-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016497/0000899243-20-016497-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016498/0000899243-20-016498-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016499/0000899243-20-016499-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320016500/0000899243-20-016500-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320017758/0000899243-20-017758-index.htm
2020-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/0000899243-20-017761-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320018121/0000899243-20-018121-index.htm
2020-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320018278/0000899243-20-018278-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320018815/0000899243-20-018815-index.htm
2020-07-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320018817/0000899243-20-018817-index.htm
2020-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000089924320024982/0000899243-20-024982-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000090342319000302/0000903423-19-000302-index.htm
2019-05-01DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1680581/000091205719000198/0000912057-19-000198-index.htm
2019-06-06DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1680581/000091205719000241/0000912057-19-000241-index.htm
2020-02-20SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000091957420001785/0000919574-20-001785-index.htm
2019-06-21S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680581/000104746919003793/0001047469-19-003793-index.htm
2019-07-08S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680581/000104746919004014/0001047469-19-004014-index.htm
2019-07-12S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680581/000104746919004158/0001047469-19-004158-index.htm
2019-07-18424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1680581/000104746919004265/0001047469-19-004265-index.htm
2019-07-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000104746919004324/0001047469-19-004324-index.htm
2019-06-21CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000110465919037024/0001104659-19-037024-index.htm
2019-06-26CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000110465919037583/0001104659-19-037583-index.htm
2019-07-128-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1680581/000110465919040208/0001104659-19-040208-index.htm
2019-07-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040331/0001104659-19-040331-index.htm
2019-07-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040333/0001104659-19-040333-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040809/0001104659-19-040809-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040810/0001104659-19-040810-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040811/0001104659-19-040811-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040812/0001104659-19-040812-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040813/0001104659-19-040813-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040814/0001104659-19-040814-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040815/0001104659-19-040815-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040816/0001104659-19-040816-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040817/0001104659-19-040817-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040818/0001104659-19-040818-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040819/0001104659-19-040819-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040820/0001104659-19-040820-index.htm
2019-07-173Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040821/0001104659-19-040821-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040965/0001104659-19-040965-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040966/0001104659-19-040966-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040967/0001104659-19-040967-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040968/0001104659-19-040968-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040969/0001104659-19-040969-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040970/0001104659-19-040970-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040971/0001104659-19-040971-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040972/0001104659-19-040972-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919040973/0001104659-19-040973-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919041303/0001104659-19-041303-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919041304/0001104659-19-041304-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm
2019-07-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000110465919041307/0001104659-19-041307-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000110465920020454/0001104659-20-020454-index.htm
2019-07-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000114036119013355/0001140361-19-013355-index.htm
2019-07-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000114420419036332/0001144204-19-036332-index.htm
2019-07-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000119312519204925/0001193125-19-204925-index.htm
2019-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312519228512/0001193125-19-228512-index.htm
2019-08-26S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1680581/000119312519228520/0001193125-19-228520-index.htm
2019-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312519262065/0001193125-19-262065-index.htm
2019-12-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312519325397/0001193125-19-325397-index.htm
2020-01-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312520001768/0001193125-20-001768-index.htm
2020-02-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000119312520025424/0001193125-20-025424-index.htm
2020-02-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000119312520025429/0001193125-20-025429-index.htm
2020-03-05S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1680581/000119312520063092/0001193125-20-063092-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1680581/000119312520124813/0001193125-20-124813-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1680581/000119312520124825/0001193125-20-124825-index.htm
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312520165696/0001193125-20-165696-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312520166654/0001193125-20-166654-index.htm
2020-06-22S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680581/000119312520175588/0001193125-20-175588-index.htm
2020-06-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000119312520177487/0001193125-20-177487-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312520181057/0001193125-20-181057-index.htm
2020-07-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000119312520197820/0001193125-20-197820-index.htm
2020-08-11S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1680581/000119312520215668/0001193125-20-215668-index.htm
2020-08-11POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1680581/000119312520215674/0001193125-20-215674-index.htm
2020-08-13CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1680581/000119312520219029/0001193125-20-219029-index.htm
2019-07-15CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1680581/000135445719000348/0001354457-19-000348-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1680581/000138713120001784/0001387131-20-001784-index.htm
2019-06-05DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1680581/000141057819000287/0001410578-19-000287-index.htm
2019-08-2610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680581/000156459019032952/0001564590-19-032952-index.htm
2019-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000156459019043359/0001564590-19-043359-index.htm
2019-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680581/000156459019043378/0001564590-19-043378-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000156459020008800/0001564590-20-008800-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1680581/000156459020008951/0001564590-20-008951-index.htm
2020-04-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000156459020014860/0001564590-20-014860-index.htm
2020-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000156459020024846/0001564590-20-024846-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680581/000156459020024866/0001564590-20-024866-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1680581/000156459020039117/0001564590-20-039117-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1680581/000156459020039121/0001564590-20-039121-index.htm
2016-07-25DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000168058116000001/0001680581-16-000001-index.htm
2017-05-10DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000168058117000001/0001680581-17-000001-index.htm
2017-07-25D/ANotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000168058117000002/0001680581-17-000002-index.htm
2018-09-05DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000168058118000002/0001680581-18-000002-index.htm
2020-06-11DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1680581/000168058120000001/0001680581-20-000001-index.htm
2019-07-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1680581/999999999519001628/9999999995-19-001628-index.htm
2020-06-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1680581/999999999520001702/9999999995-20-001702-index.htm
2020-08-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1680581/999999999520002111/9999999995-20-002111-index.htm
2020-08-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1680581/999999999520002175/9999999995-20-002175-index.htm
2019-05-13SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1680581/999999999719004388/9999999997-19-004388-index.htm
2019-06-20SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1680581/999999999719005683/9999999997-19-005683-index.htm

Fulcrum Therapeutics, Inc (FULC) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Fulcrum Therapeutics, Inc (FULC). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3552%
Institutional Ownership: 7611%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-02-19Owen B. WallaceChief Scientific OfficerSell6,088.0020.00121,760.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005299/0000899243-20-005299-index.htm
2020-05-26Owen B. WallaceChief Scientific OfficerSell412.0020.008,240.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014416/0000899243-20-014416-index.htm
2020-05-27Owen B. WallaceChief Scientific OfficerSell448.0020.008,960.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014552/0000899243-20-014552-index.htm
2020-05-28Owen B. WallaceChief Scientific OfficerSell2,232.0020.0044,640.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014719/0000899243-20-014719-index.htm
2020-06-30Owen B. WallaceChief Scientific OfficerSell141.0020.002,820.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018121/0000899243-20-018121-index.htm
2020-07-08Owen B. WallaceChief Scientific OfficerSell2,951.0020.0059,020.00127,088.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018817/0000899243-20-018817-index.htm
2020-06-30Owen B. WallaceChief Scientific OfficerBuy141.007.841,105.44127,229.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018121/0000899243-20-018121-index.htm
2020-05-26Owen B. WallaceChief Scientific OfficerBuy412.007.843,230.08127,500.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014416/0000899243-20-014416-index.htm
2020-05-27Owen B. WallaceChief Scientific OfficerBuy448.007.843,512.32127,536.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014552/0000899243-20-014552-index.htm
2020-05-28Owen B. WallaceChief Scientific OfficerBuy2,232.007.8417,498.88129,320.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014719/0000899243-20-014719-index.htm
2020-07-08Owen B. WallaceChief Scientific OfficerBuy2,951.007.8423,135.84130,039.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018817/0000899243-20-018817-index.htm
2020-02-19Owen B. WallaceChief Scientific OfficerBuy6,088.007.8447,729.92133,176.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005299/0000899243-20-005299-index.htm
2020-09-14Owen B. WallaceChief Scientific OfficerBuy6,350.007.8449,784.00133,438.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320024982/0000899243-20-024982-index.htm
2020-05-11Peter G. ThomsonVP Finance & AccountingSell7,500.0016.00120,000.0021,071.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320012820/0000899243-20-012820-index.htm
2019-07-22Third Rock Ventures IV, L.P.10% Share HolderBuy81,250.0016.001,300,000.002,343,154.00https://www.sec.gov/Archives/edgar/data/1680581/000089924319020029/0000899243-19-020029-index.htm
2020-02-24Peter G. ThomsonVP Finance & AccountingSell250.0018.614,653.0028,571.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm
2020-02-24Peter G. ThomsonVP Finance & AccountingSell2,102.0017.4336,643.3328,821.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm
2020-02-24Peter G. ThomsonVP Finance & AccountingSell2,648.0016.1842,856.5630,923.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005958/0000899243-20-005958-index.htm
2020-01-23Peter G. ThomsonVP Finance & AccountingSell262.0018.054,730.1233,571.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320002037/0000899243-20-002037-index.htm
2020-01-23Peter G. ThomsonVP Finance & AccountingSell4,738.0017.1781,371.8333,833.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320002037/0000899243-20-002037-index.htm
2020-07-08Robert J GouldOfficerSell2,500.0020.0050,000.00534,845.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018815/0000899243-20-018815-index.htm
2020-06-25Robert J GouldOfficerSell2,500.0020.8051,992.00537,345.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320017758/0000899243-20-017758-index.htm
2020-06-09Robert J GouldOfficerSell156.0020.003,120.00539,845.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015959/0000899243-20-015959-index.htm
2020-06-05Robert J GouldOfficerSell3,433.0020.1769,251.16540,001.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015784/0000899243-20-015784-index.htm
2020-06-04Robert J GouldOfficerSell1,300.0020.0426,057.98543,434.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015437/0000899243-20-015437-index.htm
2020-06-03Robert J GouldOfficerSell1,500.0020.1330,192.45544,734.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015437/0000899243-20-015437-index.htm
2020-06-02Robert J GouldOfficerSell2,797.0020.0055,940.00546,234.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015063/0000899243-20-015063-index.htm
2020-06-01Robert J GouldOfficerSell5.0020.00100.00549,031.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015063/0000899243-20-015063-index.htm
2020-05-29Robert J GouldOfficerSell1,390.0020.0827,910.78549,036.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014721/0000899243-20-014721-index.htm
2020-05-28Robert J GouldOfficerSell1,919.0020.0138,391.13550,426.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014721/0000899243-20-014721-index.htm
2020-05-26Robert J GouldOfficerSell2,500.0020.0050,000.00552,345.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014415/0000899243-20-014415-index.htm
2020-02-19Robert J GouldOfficerSell2,500.0020.0050,000.00554,845.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320005300/0000899243-20-005300-index.htm
2019-07-22 Sanofi10% Share HolderBuy93,750.0016.001,500,000.00558,035.00https://www.sec.gov/Archives/edgar/data/1680581/000089924319020073/0000899243-19-020073-index.htm
2019-07-226 Dimensions Capital, L.P.10% Share HolderBuy118,750.0016.001,900,000.00559,821.00https://www.sec.gov/Archives/edgar/data/1680581/000110465919041307/0001104659-19-041307-index.htm
2019-07-22Casdin Capital, LLC10% Share HolderBuy125,000.0016.002,000,000.00589,285.00https://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm
2019-07-22MARK J LEVINDirectorBuy81,250.0016.001,300,000.005,962,202.00https://www.sec.gov/Archives/edgar/data/1680581/000110465919041304/0001104659-19-041304-index.htm
2019-07-22Third Rock Ventures III, L.P.10% Share HolderBuy81,250.0016.001,300,000.005,962,202.00https://www.sec.gov/Archives/edgar/data/1680581/000089924319020026/0000899243-19-020026-index.htm
2019-07-22Casdin Capital, LLC10% Share HolderBuy10,000.0014.50144,996.00599,285.00https://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm
2019-07-22Casdin Capital, LLC10% Share HolderBuy5,000.0014.5072,499.00604,285.00https://www.sec.gov/Archives/edgar/data/1680581/000110465919041306/0001104659-19-041306-index.htm
2020-07-01Diego CadavidSVP Clinical DevelopmentSell1,071.0018.3019,599.3065,714.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320018278/0000899243-20-018278-index.htm
2020-03-02Diego CadavidSVP Clinical DevelopmentSell315.0018.135,709.5366,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/0000899243-20-006590-index.htm
2020-05-12Diego CadavidSVP Clinical DevelopmentSell1,860.0018.0033,480.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/0000899243-20-012822-index.htm
2020-05-28Diego CadavidSVP Clinical DevelopmentSell600.0020.0012,000.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm
2020-05-29Diego CadavidSVP Clinical DevelopmentSell200.0020.044,007.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm
2020-06-02Diego CadavidSVP Clinical DevelopmentSell45.0020.00900.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm
2020-06-03Diego CadavidSVP Clinical DevelopmentSell338.0020.186,819.5966,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm
2020-06-04Diego CadavidSVP Clinical DevelopmentSell226.0020.054,531.2566,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm
2020-06-05Diego CadavidSVP Clinical DevelopmentSell451.0020.189,100.7766,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm
2020-06-10Diego CadavidSVP Clinical DevelopmentSell401.0022.008,822.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/0000899243-20-016382-index.htm
2020-06-25Diego CadavidSVP Clinical DevelopmentSell1,459.0022.0032,098.0066,785.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/0000899243-20-017761-index.htm
2020-06-02Diego CadavidSVP Clinical DevelopmentBuy45.004.83217.3566,830.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm
2020-05-29Diego CadavidSVP Clinical DevelopmentBuy200.004.83966.0066,985.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm
2020-06-04Diego CadavidSVP Clinical DevelopmentBuy226.004.831,091.5867,011.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm
2020-03-02Diego CadavidSVP Clinical DevelopmentSell1,828.0017.2631,545.2567,100.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320006590/0000899243-20-006590-index.htm
2020-06-03Diego CadavidSVP Clinical DevelopmentBuy338.004.831,632.5467,123.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015245/0000899243-20-015245-index.htm
2020-06-10Diego CadavidSVP Clinical DevelopmentBuy401.004.831,936.8367,186.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320016382/0000899243-20-016382-index.htm
2020-06-05Diego CadavidSVP Clinical DevelopmentBuy451.004.832,178.3367,236.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320015623/0000899243-20-015623-index.htm
2020-05-28Diego CadavidSVP Clinical DevelopmentBuy600.004.832,898.0067,385.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320014722/0000899243-20-014722-index.htm
2020-06-25Diego CadavidSVP Clinical DevelopmentBuy1,459.004.837,046.9768,244.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320017761/0000899243-20-017761-index.htm
2020-05-12Diego CadavidSVP Clinical DevelopmentBuy1,860.004.838,983.8068,645.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320012822/0000899243-20-012822-index.htm
2020-02-03Diego CadavidSVP Clinical DevelopmentSell2,143.0017.3337,141.8368,928.00https://www.sec.gov/Archives/edgar/data/1680581/000089924320003272/0000899243-20-003272-index.htm